Stockscreener 앱 받기
8.32
3.10%
0.25
시간 외 거래:
8.32
전일 마감가:
$8.07
열려 있는:
$8.01
하루 거래량:
134.97K
Relative Volume:
1.26
시가총액:
$53.68M
수익:
$5.75M
순이익/손실:
$-38.96M
주가수익비율:
-0.6672
EPS:
-12.47
순현금흐름:
$-32.63M
1주 성능:
+12.74%
1개월 성능:
+51.96%
6개월 성능:
-0.72%
1년 성능:
+32.48%
1일 변동 폭
$7.51
$8.45
1주일 범위
$7.13
$8.45
52주 변동 폭
$2.92
$11.20
칼라 파마슈티컬스 Stock (KALA) Company Profile
명칭
Kala Bio Inc
전화
781-996-5252
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
KALA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
8.32 | 55.26M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Ladenburg Thalmann | Buy |
| 2022-03-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-07-23 | 개시 | Northland Capital | Outperform |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-27 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-09 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 개시 | Jefferies | Buy |
모두보기
칼라 파마슈티컬스 주식(KALA)의 최신 뉴스
Using Python tools to backtest KALA BIO Inc. strategiesGold Moves & AI Forecast for Swing Trade Picks - Newser
Can KALA BIO Inc. recover in the next quarterJuly 2025 Decliners & Consistent Growth Equity Picks - Newser
What’s next for KALA BIO Inc. stock price2025 Sector Review & Real-Time Buy Signal Notifications - Newser
Is KALA BIO Inc. a Top Dividend Stock to Watch in 2025Earnings Risk Summary & Weekly Watchlist for Consistent Profits - Newser
Price momentum metrics for KALA BIO Inc. explainedQuarterly Profit Review & Weekly Breakout Stock Alerts - Newser
KALA BIO Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Movers & AI Optimized Trading Strategy Guides - Newser
KALA BIO Inc. stock trend forecastCEO Change & Smart Money Movement Alerts - Newser
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade - MSN
Institutional Tools Highlight Unusual Flow in KALA BIO Inc.Bear Alert & Low Risk Growth Stock Ideas - newsyoung.net
KALA BIO Inc. Building a Base Near Support2025 Retail Activity & Proven Capital Preservation Tips - sundaytimes.kr
Technical analysis overview for KALA BIO Inc. stockMarket Performance Recap & Real-Time Volume Trigger Notifications - Newser
Comparing KALA BIO Inc. in custom built stock radars2025 Risk Factors & Intraday High Probability Alerts - Newser
Statistical indicators supporting KALA BIO Inc.’s strengthNew Guidance & Safe Entry Point Alerts - Newser
Is KALA BIO Inc. showing insider buyingROIC-Focused Investment List - thegnnews.com
Why KALA BIO Inc. stock attracts strong analyst attentionMachine Learning Stock Movement Detector - Newser
How KALA BIO Inc. stock performs during market volatilityShort-Term Market Movement Forecast Report - Newser
Using portfolio simulators with KALA BIO Inc. includedFree Swing Setup With Technical Confirmation - Newser
What makes KALA BIO Inc. stock price move sharplyFree Risk Managed Intraday Trade Alerts - Newser
Can volume confirm reversal in KALA BIO Inc.Free AI Screening for Swing Trade Picks - Newser
Kala Bio Reports Q2 2025 Earnings: EPS -$1.82, Revenue Unavailable; Focus on Advancing KPI-012 for Rare Eye Diseases. - AInvest
Trend analysis for KALA BIO Inc. this weekWeekly Trend Watch with Market Signals - Newser
What drives KALA BIO Inc.’s stock priceStocks with 300% Upside - sisaissue.com
KALA BIO: Q2 Earnings Snapshot - Greenwich Time
KALA BIO (NASDAQ:KALA) Stock Rating Lowered by Wall Street Zen - Defense World
Momentum divergence signals in KALA BIO Inc. chartShort-Term Profit Alert With Entry Forecast - Newser
Kala Bio (KALA) Q2 Loss Widens 15% - AOL.com
KALA BIO Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kala Bio Q2 Loss Widens 15%, KPI-012 Enrollment Completed - AInvest
Biotech's Long Game: Assessing KALA BIO's Q2 Loss in the Context of Strategic Innovation - AInvest
Kala Bio (KALA) Q2 Loss Widens 15% - The Motley Fool
KALA BIO, Inc. Completes Patient Enrollment in Phase 2b CHASE Trial for KPI-012 in Persistent Corneal Epithelial Defect, Reports Financial Results and Upcoming Milestones - Quiver Quantitative
KALA BIO, Inc. SEC 10-Q Report - TradingView
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
KALA Bio Completes Phase 2b Trial Enrollment for Novel PCED Eye Treatment | KALA Stock News - Stock Titan
KALA BIO Reports Second Quarter 2025 Financial Results and Provi - GuruFocus
칼라 파마슈티컬스 (KALA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
칼라 파마슈티컬스 주식 (KALA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 24 '25 |
Sale |
4.01 |
3,631 |
14,560 |
62,100 |
| Bazemore Todd | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
4,058 |
16,273 |
83,699 |
| Brazzell Romulus K | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
5,251 |
21,057 |
82,698 |
| Iwicki Mark T | Director |
Jun 24 '25 |
Sale |
4.01 |
13,227 |
53,040 |
258,433 |
0.41%
0.88%
자본화:
|
볼륨(24시간):